Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin

Area of Science:

• Immunology
• Dermatology
• Neuroimmunology

Background:

• Interferon beta (IFNβ) is a primary treatment for multiple sclerosis (MS).
• Subcutaneous (s.c.) administration of IFNβ is linked to higher immunogenicity and antidrug antibody development compared to other routes.
• The role of skin-resident dendritic cells (DCs) in IFNβ immunogenicity is not fully understood.

Purpose of the Study:

• To investigate the impact of intradermal (i.d.) and subcutaneous (s.c.) IFNβ administration on skin-resident cells.
• To compare the immunogenicity of different IFNβ preparations when administered at normalized doses and injection sites.

Main Methods:

• Human skin explant model for ex vivo intradermal IFNβ injection.
• In vivo subcutaneous IFNβ injection in MS patients.
• Analysis of dermal dendritic cell migration, CD86 expression, HLA-DR expression, and inflammatory cytokine levels in skin biopsies.

Main Results:

• Intradermal IFNβ reduced dermal DC migration and enhanced CD86 expression ex vivo.
• Subcutaneous IFNβ increased HLA-DR expression in vivo.
• Both administration routes elevated inflammatory cytokine expression in skin biopsies compared to controls.
• Different IFNβ preparations induced similar immune responses at normalized doses and sites.

Conclusions:

• IFNβ affects skin-resident cells, influencing DC function and inflammatory responses.
• The route and frequency of IFNβ administration are key factors in its immunogenicity.
• Differences in immunogenicity between IFNβ treatments are likely attributable to administration logistics rather than the drug formulation itself.